Vividion Therapeutics Revenue and Competitors

CA USA

Location

#5529

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Vividion Therapeutics's estimated annual revenue is currently $52.3M per year.(i)
  • Vividion Therapeutics's estimated revenue per employee is $193,750
  • Vividion Therapeutics's total funding is $271M.

Employee Data

  • Vividion Therapeutics has 270 Employees.(i)
  • Vividion Therapeutics grew their employee count by 29% last year.

Vividion Therapeutics's People

NameTitleEmail/Phone
1
VP, Head Early Discovery ChemistryReveal Email/Phone
2
SVP Project Management, Project Leadership and Business OperationsReveal Email/Phone
3
VP, Head ChemistryReveal Email/Phone
4
Head Information TechnologyReveal Email/Phone
5
VP FinanceReveal Email/Phone
6
VP, Clinical DevelopmentReveal Email/Phone
7
VP, Intellectual PropertyReveal Email/Phone
8
Head BiologyReveal Email/Phone
9
SVP Operations and AlliancesReveal Email/Phone
10
SVP Translational ScienceReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Vividion Therapeutics?

Vividion is a next-generation biotechnology company focused on expanding the therapeutic potential of small molecules. Making accessible the broad set of proteins expressed in human cells, the company's cutting-edge platform was spun out of the labs of Vividion's scientific founders, a team of experts in chemical biology and synthetic chemistry from The Scripps Research Institute in La Jolla, CA. Vividion is committed to advancing and applying its pioneering proteome-wide drug discovery to create life-changing therapeutics.

keywords:N/A

$271M

Total Funding

270

Number of Employees

$52.3M

Revenue (est)

29%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Vividion Therapeutics News

2022-04-06 - Difficult-to-treat inflammatory bowel disease: results from a ...

... Protagonist Therapeutics, Reistone Biopharma, Roche, Sandoz, Second Genome, Takeda, Teva Pharmaceuticals, Topivert Pharma, and Vividion Therapeutics;...

2021-08-05 - Bayer : strengthens drug discovery platform through acquisition of Vividion Therapeutics

Thursday - August 5, 2021 Bayer strengthens drug discovery platform through acquisition of Vividion Therapeutics Acquisition strengthens Bayer's drug discovery capabilities with cutting-edge chemoproteomics platform / Vividion's unique approach identifies previously unknown binding pockets in u ...

2021-02-24 - Biotech Vividion lands $135M in crossover cash, paving a path to the public markets

The Series C round of financing announced Wednesday included so-called crossover investors, firms that invest in both public and private companies. Securing crossover investment is one of the steps companies take as they prepare for an IPO. Preclinical-stage Vividion is developing small molecul ...

2019-05-05 - Vividion’s ‘Unique’ Platform Draws $82M Series B Round

Vividion’s Paige Schaffer works in the company’s lab at its prior location. The company’s drug-discovery platform targets “undruggable” proteins. Photo by Jamie Scott Lytle. Vividion Therapeutics — which formed to transform drug development by targeting “undruggable” proteins — has attracted an ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$42.1M27032%$40M
#2
$29.7M270N/AN/A
#3
$80.2M2705%N/A
#4
$29.7M2700%N/A
#5
$78.7M270N/AN/A